Table 1.

Baseline characteristics of patients receiving pembrolizumab plus dinaciclib

Characteristic	Pembrolizumab + dinaciclib
	rrCLL, n = 17	rrDLBCL, n = 38	rrMM, n = 17	All disease cohorts, N = 72
Sex, n (%)
Male	14 (82.4)	23 (60.5)	6 (35.3)	43 (59.7)
Female	3 (17.6)	15 (39.5)	11 (64.7)	29 (40.3)
Age, y
$<65$, n (%)	4 (23.5)	19 (50.0)	12 (70.6)	35 (48.6)
$\ge 65$, n (%)	13 (76.5)	19 (50.0)	5 (29.4)	37 (51.4)
Median (range)	69.0 (50-85)	64.5 (39-85)	62.0 (42-74)	65.0 (39-85)
Race, n (%)
White	16 (94.1)	32 (84.2)	14 (82.4)	62 (86.1)
Asian	0 (0.0)	4 (10.5)	0 (0.0)	4 (5.6)
Black or African American	1 (5.9)	2 (5.3)	3 (17.6)	6 (8.3)
Ethnicity, n (%)
Hispanic or Latino	0 (0.0)	4 (10.5)	1 (5.9)	5 (6.9)
Not Hispanic or Latino	17 (100.0)	34 (89.5)	16 (94.1)	67 (93.1)
Baseline ECOG PS, n (%)
0: normal activity	8 (47.1)	16 (42.1)	8 (47.1)	32 (44.4)
1: symptomatic but ambulatory	9 (52.9)	22 (57.9)	9 (52.9)	40 (55.6)
Primary diagnosis, n (%)
CLL, not otherwise specified	17 (100.0)	0 (0.0)	0 (0.0)	17 (23.6)
DLBCL, not otherwise specified	0 (0.0)	38 (100.0)	0 (0.0)	38 (52.8)
MM	0 (0.0)	0 (0.0)	17 (100.0)	17 (23.6)
Previous lines of therapy, n (%)
1	3 (17.6)	0 (0.0)	0 (0.0)	3 (4.2)
2	5 (29.4)	16 (42.1)	1 (5.9)	22 (30.6)
3	4 (23.5)	8 (21.1)	2 (11.8)	14 (19.4)
4	2 (11.8)	10 (26.3)	3 (17.6)	15 (20.8)
$\ge 5$	3 (17.6)	4 (10.5)	11 (64.7)	18 (25.0)
Previous therapies
Antineoplastics, n (%)
Bortezomib	0 (0.0)	0 (0.0)	16 (94.1)	16 (21.9)
Immunosuppressants, n (%)
Lenalidomide	0 (0.0)	1 (2.6)	17 (100.0)	18 (24.7)
Pembrolizumab doses
Median number	3	3	2	3
Time on study treatment, d
Median (range)	50 (1-492)	51 (1-471)	29 (8-71)	49 (1-492)